Drug Prices
Commentary
Read about problems with drug price controls
Let’s Hope Drug Companies Win Price Controls War
The IRA gives federal officials the authority to dictate what Medicare pays for certain medicines — a scheme intended to reduce the government’s drug bill. Late last month, the Department of Health and Human Services announced the first 10 drugs subject to the law’s price controls, which include the blood thinners
Commentary
Read about problems of PBMs
Congress Waking Up to PBMs Drug Cost Manipulations
PBMs work for (or increasingly are part of) insurance companies. They decide which drugs patients can access and negotiate rebates to drugs’ list prices. The term “rebates” sounds like these discounts should benefit patients, but PBMs and insurers pocket these savings while basing patients’ costs on the higher undiscounted prices.
Commentary
Read latest about problems with PBMs
Pharmacy benefit manager reform must remain a priority for Congress
Congress has returned to Capitol Hill from summer recess. Lawmakers in both chambers have a full slate of policy priorities to attend to — not least among them funding the government and averting a shutdown before the Sept. 30 deadline. Several healthcare items will also remain near the top of
Commentary
Government Regulation Threatens Life-Saving Innovation
Drug Companies Are Delivering a “Golden Age of Medicine.” Let’s Protect It.
New vaccines for scourges like malaria and respiratory syncytial virus, or RSV. New cancer drugs that can cut death rates by half or even cause complete remission. The discovery of a biomarker that could identify people who would benefit from investigational drugs for Parkinson’s Disease. Breakthrough treatments that curb obesity
Commentary
Learn how price controls threaten access to drugs
Despite Democrats’ Celebratory Mood, It’s A Sad Day For American Patients.
President Joe Biden celebrated a milestone today—but American patients have no reason to cheer. The White House announced the first 10 prescription drugs that, starting in 2026, will be subject to price controls authorized by the Inflation Reduction Act . . . It’s laudable that lawmakers want to reduce out-of-pocket
Commentary
Read latest on government price controls
Medicaid Drug Price Transparency Rule Is More Sinister Than It Seems
The Biden administration claims to support price transparency in healthcare. The Centers for Medicare and Medicaid Services has formally warned hundreds of hospitals to comply with federal rules requiring them to post their prices publicly. And the agency just rolled out a new rule designed to “advance prescription drug transparency
Commentary
Read the latest about PBMs
It’s Time To End the PBM Shakedown
Who says bipartisanship is dead? In the House and Senate, members of both parties are advancing legislation to check the power of pharmacy benefit managers (PBMs), the self-dealing middlemen in the drug supply chain that inflate Americans’ spending on prescriptions by billions of dollars a year. By shining a light
Blog
Read more about broken 340B program
340B Advocates Strike Back
There are many reasons why government programs fail to deliver on their intentions, regardless of how well meaning they may be. The rhetoric from too many 340B recipients exemplifies a primary obstacle: Reforms that are necessary to correct a program’s glaring flaws or its fundamental unsustainability are demagogued and labeled
Commentary
Read latest on drug pricing
The Continuing Danger From Progressive’s Faulty Excess Profit Allegations
Sen. Bernie Sanders (D-Vermont) and Rep. Alexandria Ocasio-Cortez (D-New York) continuously confirm Alexander Pope’s famous maxim about a little bit of knowledge. It truly is a dangerous thing, especially in the hands of politicians. During a May 11th meeting of the Senate Health, Education, Labor and Pensions (HELP) committee, Sen.
Blog
Key Takeaways from President Biden’s Proposed 2024 Healthcare Budget
The United States currently faces a deficit of over $700 billion. Not including other health programs, in 2021, over $734 billion was spent on Medicaid alone. Despite these facts, President Biden’s 2024 budget proposal aims to increase funding for healthcare by 11.5%. The proposal claims proposed tax increases will not
Read about problems with drug price controls
Let’s Hope Drug Companies Win Price Controls War
The IRA gives federal officials the authority to dictate what Medicare pays for certain medicines — a scheme intended to reduce the government’s drug bill. Late last month, the Department of Health and Human Services announced the first 10 drugs subject to the law’s price controls, which include the blood thinners
Read about problems of PBMs
Congress Waking Up to PBMs Drug Cost Manipulations
PBMs work for (or increasingly are part of) insurance companies. They decide which drugs patients can access and negotiate rebates to drugs’ list prices. The term “rebates” sounds like these discounts should benefit patients, but PBMs and insurers pocket these savings while basing patients’ costs on the higher undiscounted prices.
Read latest about problems with PBMs
Pharmacy benefit manager reform must remain a priority for Congress
Congress has returned to Capitol Hill from summer recess. Lawmakers in both chambers have a full slate of policy priorities to attend to — not least among them funding the government and averting a shutdown before the Sept. 30 deadline. Several healthcare items will also remain near the top of
Government Regulation Threatens Life-Saving Innovation
Drug Companies Are Delivering a “Golden Age of Medicine.” Let’s Protect It.
New vaccines for scourges like malaria and respiratory syncytial virus, or RSV. New cancer drugs that can cut death rates by half or even cause complete remission. The discovery of a biomarker that could identify people who would benefit from investigational drugs for Parkinson’s Disease. Breakthrough treatments that curb obesity
Learn how price controls threaten access to drugs
Despite Democrats’ Celebratory Mood, It’s A Sad Day For American Patients.
President Joe Biden celebrated a milestone today—but American patients have no reason to cheer. The White House announced the first 10 prescription drugs that, starting in 2026, will be subject to price controls authorized by the Inflation Reduction Act . . . It’s laudable that lawmakers want to reduce out-of-pocket
Read latest on government price controls
Medicaid Drug Price Transparency Rule Is More Sinister Than It Seems
The Biden administration claims to support price transparency in healthcare. The Centers for Medicare and Medicaid Services has formally warned hundreds of hospitals to comply with federal rules requiring them to post their prices publicly. And the agency just rolled out a new rule designed to “advance prescription drug transparency
Read the latest about PBMs
It’s Time To End the PBM Shakedown
Who says bipartisanship is dead? In the House and Senate, members of both parties are advancing legislation to check the power of pharmacy benefit managers (PBMs), the self-dealing middlemen in the drug supply chain that inflate Americans’ spending on prescriptions by billions of dollars a year. By shining a light
Read more about broken 340B program
340B Advocates Strike Back
There are many reasons why government programs fail to deliver on their intentions, regardless of how well meaning they may be. The rhetoric from too many 340B recipients exemplifies a primary obstacle: Reforms that are necessary to correct a program’s glaring flaws or its fundamental unsustainability are demagogued and labeled
Read latest on drug pricing
The Continuing Danger From Progressive’s Faulty Excess Profit Allegations
Sen. Bernie Sanders (D-Vermont) and Rep. Alexandria Ocasio-Cortez (D-New York) continuously confirm Alexander Pope’s famous maxim about a little bit of knowledge. It truly is a dangerous thing, especially in the hands of politicians. During a May 11th meeting of the Senate Health, Education, Labor and Pensions (HELP) committee, Sen.
Key Takeaways from President Biden’s Proposed 2024 Healthcare Budget
The United States currently faces a deficit of over $700 billion. Not including other health programs, in 2021, over $734 billion was spent on Medicaid alone. Despite these facts, President Biden’s 2024 budget proposal aims to increase funding for healthcare by 11.5%. The proposal claims proposed tax increases will not
